Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | L1₹18,832Qualified | L1 | Qualified MSE, MII, Category: General | |
| 2 | L2₹1.3 L+₹1.1 L (592.3%)Qualified B NO 62 SHAHEED UDHAM SINGH NAGAR JALANDHAR PUNJAB 144001 | JALANDHAR | PUNJAB | 144001 | L2 | Qualified MSE, MII, Category: General | |
| 3 | L3₹1.4 L+₹1.2 L (622.6%)Qualified TC 13 1678 4 V STAB APARTMENT MEDICAL COLLEGE P O MURINJAPALAM THIRUVANANTHAPURAM KERALA 695011 | THIRUVANANTHAPURAM | KERALA | 695011 | L3 | Qualified MII | |
| 4 | L4₹1.4 L+₹1.2 L (650.2%)Qualified | L4 | Qualified MSE, MII, Category: OBC | |
| 5 | L5₹1.5 L+₹1.3 L (691.2%)Qualified 1ST FLOOR SHOP NO 119 CS OCF OMEGA MALL STREET NO 5 ROHINI SECTOR 25 ROHINI SECTOR 25 NEW DELHI NORTH WEST DELHI DELHI 110085 | NORTH WEST DELHI | DELHI | 110085 | L5 | Qualified MSE, MII, Category: OBC |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
25 Feb 2025, 11:00 amClosed
Anastrazole 1 mg Tab
Tab Folic Acid 5 mg
Deflazacort 6 mg Tab
Tab Iguratimod 25 mg
Ezetimibe 10 mg Tab
Rosuvastatin 40 mg Tab
Methotrexate 10 mg Tab
Inj Degludec or Insulin Aspart of Recombinant DNA Origin of 70 percent Insulin Degludec and 30 percent Insulin Aspart 100 IU or Ml of 3 ml
Inj Insulin Aspart 100 IU or ml Inj of Monocomponent r DNA Originof 300 IU or 3ml Catridges of Novorapid Penfill
Inj Insulin Aspart 100 IU or Ml Monocomponent DNA Origin of 300 IU or 3ML Pen
Recombinant Somatropin for Injection 36 IU of 12 mg or ml
Tab Mesalamine 1 point 2 gm
Mesalamine Suppository 500 mg
Tab Glimepride 2 mg
Tab Dapagliflozin 10 mg
Tab Vildagliptin 50 mg
Cilnidipine 10 mg Tab
Telmisartan 40 mg Tab
Silodosin 8 mg Tab
Inj Zolendronic Acid 4 mg
7423380
GEM/2025/B/5861873
Two Packet Bid
Anastrazole 1 mg Tab
30 days
Kannur, Kerala
Total value wise evaluation
BOQ
7 documents required · 7 mandatory
3 yrs
₹3
50%
Exempted
4 Feb 2025
4 Feb 2025
25 Feb 2025
PROCUREMENT OF MEDICINES
Anastrazole 1 mg Tab
Tab Folic Acid 5 mg
Deflazacort 6 mg Tab
Tab Iguratimod 25 mg
Ezetimibe 10 mg Tab
Rosuvastatin 40 mg Tab
Methotrexate 10 mg Tab
Inj Degludec or Insulin Aspart of Recombinant DNA Origin of 70 percent Insulin Degludec and 30 percent Insulin Aspart 100 IU or Ml of 3 ml
Inj Insulin Aspart 100 IU or ml Inj of Monocomponent r DNA Originof 300 IU or 3ml Catridges of Novorapid Penfill
Inj Insulin Aspart 100 IU or Ml Monocomponent DNA Origin of 300 IU or 3ML Pen
Recombinant Somatropin for Injection 36 IU of 12 mg or ml
Tab Mesalamine 1 point 2 gm
Mesalamine Suppository 500 mg
Tab Glimepride 2 mg
Tab Dapagliflozin 10 mg
Tab Vildagliptin 50 mg
Cilnidipine 10 mg Tab
Telmisartan 40 mg Tab
Silodosin 8 mg Tab
Inj Zolendronic Acid 4 mg
Anastrazole 1 mg Tab
Tab Folic Acid 5 mg
Deflazacort 6 mg Tab
Tab Iguratimod 25 mg
Ezetimibe 10 mg Tab
Rosuvastatin 40 mg Tab
Methotrexate 10 mg Tab
Inj Degludec/Insulin Aspart(Recombinant DNA Origin) 70 % Insulin Degludec and 30% Insulin Aspart 100 IU/Ml
Inj Insulin Aspart 100 IU/ml Inj (Monocomponent r-DNA Origin) 300 IU/3ml Catridges (Novorapid Penfill)
Inj Insulin Aspart 100 IU/Ml Monocomponent DNA Origin)300 IU/3ML Pen
Recombinant Somatropin for Injection 36 IU(12 mg/ml)
Tab Mesalamine 1.2 gm
Mesalamine Suppository 500 mg
Tab Glimepride 2 mg
Tab Dapagliflozin 10 mg
Tab Vildagliptin 50 mg
Cilnidipine 10 mg Tab
Telmisartan 40 mg Tab
Silodosin 8 mg Tab
Inj Zolendronic Acid 4 mg
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_7423380.pdf
GEM_BID
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
re-07_annex_e_2025-01-24-10-05-13_b3e4039d2aefe92af086a322ef01f313.pdf
BOQ
boq_item_sample_filer-re-07_24-25_2025-01-24-10-05-13_1d449cc98b43128b103f58b9056738d2.csv.pdf
BOQ
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .